Zelluna ASA (ZLNA)

Overview

Zelluna ASA is a biotechnology company at the forefront of developing revolutionary 'off-the-shelf' T cell receptor (TCR) guided natural killer (NK) cell therapies, referred to as TCR-NK. The company focuses on addressing advanced solid cancers, including those affecting the lung, ovaries, breasts, and head & neck regions. Zelluna's mission is to provide transformative and curative treatments by merging clinically validated TCR targeting with the robust effector capabilities of allogeneic NK cells. This innovative approach enables enhanced cancer detection, scalability, and global access, successfully circumventing the limitations often encountered with therapies that predominantly target liquid cancers. The company's lead program, ZI-MA4-1, is recognized as the world’s first MAGE-A4 targeting TCR-NK therapy and is currently advancing towards Phase I clinical trials after securing a NOK 58 million investment in November 2025, aimed at generating initial patient data and furthering its development pipeline. Established in March 2025 through the merger of Zelluna Immunotherapy AS and Ultimovacs ASA, Zelluna ASA operates from the Oslo Cancer Cluster Innovation Park in Norway. The company is led by a team of seasoned biotechnology executives with substantial experience in TCR, immunotherapy, and cell therapies, spanning the entire journey from discovery to commercialization. Zelluna ASA plays a crucial role in the cell therapy industry, bolstered by key foundational patents and a proprietary manufacturing process tailored for large-scale production, positioning it to meet significant unmet needs in the lucrative global oncology market.

Products and Services

• TCR-NK Cell Therapies

  Zelluna ASA specializes in the development of TCR-NK cell therapies designed to treat solid tumors by harnessing the specificity of T cell receptors to enhance the targeting and efficacy of natural killer cells. This approach aims to improve cancer treatment outcomes and address existing challenges in the field.

• Lead Program ZI-MA4-1

  The lead therapeutic candidate, ZI-MA4-1, is a pioneering formulation targeting the melanoma-associated antigen MAGE-A4. This program has reached the brink of Phase I clinical trials, signifying a significant step forward in developing effective therapies for difficult-to-treat cancers.

• Clinical Trial Execution

  Zelluna ASA is dedicated to conducting extensive clinical trials to validate the effectiveness and safety of its therapies. These trials will facilitate the generation of patient data critical for the advancement of its treatment offerings and enable the company to secure regulatory approvals.

• Proprietary Manufacturing Process

  The company has developed a unique manufacturing process capable of producing TCR-NK therapies at scale. This proprietary technology ensures high-quality, consistent product output, essential for meeting the demands of the healthcare market and ensuring global accessibility.

• Intellectual Property Protections

  Zelluna ASA holds a portfolio of essential patents that safeguard its innovations in the TCR-NK therapy space. These protections provide the company with a competitive edge in the biotech arena, allowing for continued advancement and commercialization of its products.